-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550

Benzinga·08/04/2026 16:28:09
語音播報
TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.